Abstract:Psoriasis is a chronic inflammatory disease with a complex pathophysiology and a multigenic background. Autoimmunity and genetic hallmarks couple to confer the disease, which is characterized by chronic plaques (85-90% of all cases) and/or psoriasis arthritis (PsA), and involve the peripheral and sacro-iliac joints, nails, and skeleton. Dissecting the ethiopathogenetic mechanisms of psoriasis and PsA is a major basic research challenge. One important question is whether a single inflammatory mediator can be responsible for the interactive network that forms between immune cells and cytokines in this disease. Despite much progress, no research has yet been able to define a single model to explain the multifaceted pathogenesis of psoriasis and PsA. It is known that both the innate and adaptive immune systems are involved, antigen presenting cells and T lymphocytes play a prominent role, and that the deregulation of the T helper (Th)- 1/Th-2/Th-17/Th-23 axis is directly implicated in disease pathogenesis. Pharmacological therapy for psoriasis has evolved with the development of human knowledge of the disease pathophysiology. Thus, the first "ethiopathogenetic" drugs (e.g., methotrexate, cyclosporin, and alefacept) inhibited T-cell activation directly or targeted co-accessory molecules implicated in T-cell activation. When the mechanism underlying psoriatic inflammation was accepted as a cytokine network disorder, more specific biologics were studied in murine models and were later used clinically. Tumor necrosis factor was the first successful target of cytokine inhibition therapy for psoriasis and PsA (e.g., infliximab, adalimumab, and etanercept). With the recently discovered role for Th-17 in autoimmunity, drugs targeting interleukin-23 (ustekinumab) have become accepted for the pharmacological treatment of psoriasis. The expansion of pharmacological treatment options for psoriasis is not complete. As the knowledge of pathogenetic mechanisms increases, it may be possible to design therapeutic approaches that selectively target the ethiopathogenetic cells or cytokines while sparing the others. In this way, using a more targeted drug therapy may preserve the integrity of the immune system. Thus, one great struggle in treating this complex disease is the challenge to synthesize the "perfect" drug.

CURRENT UNDERSTANDING OF PSORIASIS IMMUNOPATHOGENESIS: A NARRATIVE REVIEW

Current Concepts of Psoriasis Immunopathogenesis

Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances

Etiopathogenesis of Psoriasis: Integration of Proposed Theories

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

Psoriasis. Definition and Classification of A Complex Entity

Psoriasis Pathogenesis and Treatment

Psoriasis - a review of recent progress, characteristics, diagnostic management

The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

The Current Advancement in Psoriasis

A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions

Immune responses and therapeutic options in psoriasis

Pathogenesis, Multi-Omics Research, and Clinical Treatment of Psoriasis.

The Prevalence and Risk Factors of Psoriasis

Periodontitis in Psoriatic Patients: Epidemiological Insights and Putative Etiopathogenic Links

Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis

Advances in psoriasis research: From pathogenesis to therapeutics

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

Pathophysiology of psoriasis: A review

Recent update on immunopathogenesis of psoriasis